Categories
Change Password!
Reset Password!
In type 2 diabetes mellitus, DPP-4 inhibitors achieve better glycemic outcomes with fewer hypoglycemic events than sulfonylureas.
Managing type 2 diabetes mellitus (T2DM) involves keeping blood sugar levels under control while reducing treatment-related risks. Although sulfonylureas are widely used, they are often associated with hypoglycemia. Dipeptidyl peptidase-4 (DPP-4) inhibitors offer a safer alternative due to their glucose-dependent action.
In this hospital-based study, a group of researchers compared glycemic control and hypoglycemia episodes between these two treatment approaches in 102 adults with T2DM. Volunteers were divided into two groups: one receiving sulfonylurea-based therapy and the other treated with DPP-4 inhibitor–based regimens. From patient interviews and medical records, data was collected. Blood sugar control was evaluated using fasting plasma glucose, postprandial plasma glucose, and glycated hemoglobin (HbA1c).
Hypoglycemia episodes were recorded based on patient reports and clinical documentation. Patients receiving DPP-4 inhibitors reported markedly better glycemic control, reflected in lower mean HbA1c levels and a higher proportion achieving target HbA1c below 7%. Safety outcomes strongly favored DPP-4 inhibitors. The incidence of hypoglycemia—especially recurrent and severe episodes—was substantially higher in the sulfonylurea group (Table 1).
Overall, DPP-4 inhibitors were associated with improved glycemic control and fewer hypoglycemia episodes when compared to sulfonylureas. This supports their role as a safer and effective option in the management of T2DM.
International Journal of Life Sciences, Biotechnology and Pharma Research
Comparison of Glycemic Control and Hypoglycemia Episodes in Patients on Sulfonylurea vs DPP-4 Inhibitors
Abhinav Sharma et al.
Comments (0)